相关临床试验
43
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1874
已完成
25
58.1%
尚未招募
3
7.0%
招募中
5
11.6%
终止
3
7.0%
Unknown
7
16.3%
暂无批准数据
- Australia is preparing to launch the world's first clinical trial of PaedNeoVax (PTX-108), a personalized mRNA vaccine for children with aggressive brain tumors, though a start date has not yet been set. - The vaccine uses small samples of a patient's tumor to engage T cells to detect and attack cancer markers on tumor cell surfaces, with the trial led clinically by Professor Jordan Hansford of SAHMRI and the University of Adelaide. - The federal government has supported PTX-108 development with a $2.58 million Medical Research Future Fund grant, while the family of 16-year-old Coby Metzler, diagnosed with diffuse midline glioma, is seeking compassionate access outside the trial. - Experts emphasize that clinical trials are necessary to establish the safety blueprint needed to protect children from potential harm, even as advocates call for faster access to experimental treatments.
- An 18-month clinical trial found intermittent fasting and continuous calorie restriction produced similar weight loss of about seven kilograms at six months in adults with obesity. - Participants using intermittent fasting did not feel they needed to constantly monitor eating or count calories, unlike those on calorie-restricted diets. - The calorie restriction group reported that conscious control over eating accounted for approximately 15% of their weight loss. - Researchers suggest intermittent fasting could provide an alternative for individuals who struggle with conventional dieting, supporting more personalized weight management strategies.
- A study in the British Journal of Clinical Pharmacology found only 10% of Australian consumers and 52% of healthcare professionals are aware of the TGA's Black Triangle Scheme. - The scheme, launched in 2018, uses a black inverted triangle to flag newly approved medicines and older drugs with new indications for enhanced side-effect monitoring. - Once the scheme was explained, 66% of participants said they would be likely to report side effects for black triangle medicines, indicating strong latent support. - Researchers call for systemic integration into prescribing software, larger and more prominent labeling, and improved education for GPs and pharmacists.
- The ESPRESSo trial found that high-intensity therapy starting within two weeks of stroke did not improve hand and arm recovery beyond standard care, challenging the "more therapy, earlier" approach. - Sixty-four stroke survivors received an extra 90 minutes of daily therapy for three weeks, but showed identical three-month outcomes to patients receiving standard care alone. - The study suggests early stroke recovery is dominated by natural biological repair processes that cannot be enhanced by increasing therapy dose above standard care. - Results indicate that intensive therapy may be more effective later in recovery when patients can engage more fully, rather than during the acute phase.
- Australian researchers at the University of Adelaide are recruiting participants for a clinical trial to develop the world's first diagnostic test for long COVID, addressing a critical gap in current medical practice. - The trial builds on previous studies showing that COVID-19 can disrupt the immune system long after initial infection, with those experiencing the most severe immune dysfunction later developing long COVID symptoms. - Around 5 percent of patients experience persistent symptoms like fatigue, brain fog, and chest pain for over three months after infection, sometimes lasting a year regardless of age or initial infection severity. - The study will collect blood samples and symptom questionnaires from long COVID volunteers, with follow-up testing to track biomarkers as symptoms potentially improve.
- Microbiotica has completed patient recruitment for its COMPOSER-1 Phase 1b trial, enrolling 29 adults with ulcerative colitis across five European countries. - The randomized, placebo-controlled study is evaluating MB310, an oral live biotherapeutic containing eight bacterial strains designed to induce long-term remission without immunosuppression. - Initial results from the 12-week treatment period followed by 12-week observation are expected by the end of 2025. - MB310 was developed based on analysis of faecal microbiota transplant data and acts through three mechanisms targeting ulcerative colitis pathology.
- 4DMedical renewed its three-year contract with University of Michigan Medical Center, valued at approximately AUD$155,000, to provide access to advanced lung analysis applications through 2028. - A recent multicentre study published in Respiratory Research demonstrated that 4DMedical's XV LVAS® technology can detect early small airways disease often missed by standard diagnostic tests. - The company secured AUD$1.1 million in government funding through Australia's Economic Accelerator program to develop AI-derived functional biomarkers for enhanced respiratory disease diagnosis and treatment.
- Microbiotica has dosed the first patient in its Phase 1b COMPOSER-1 trial of MB310, an oral precision microbiome medicine for ulcerative colitis patients. - The international trial will recruit up to 30 patients across five countries to evaluate the safety and efficacy of the eight-strain bacterial consortium. - MB310 was developed using clinical data from faecal microbiota transplant studies and acts through three mechanisms targeting UC pathology. - Initial data readouts are expected by the end of 2025 for this novel live biotherapeutic product approach to inflammatory bowel disease.
